+143%

est. 2Y upside i

Series A

Rank

#136

Sector

Synthetic Biology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Enzymit presents a strong equity opportunity for a job seeker, driven by its proprietary AI-powered cell-free bioproduction platform and recent success in scaling hyaluronic acid production.

Last updated: March 10, 2026

Bull (25%)+350%

Enzymit successfully scales its cell-free hyaluronic acid production beyond pilot stage and secures multiple large-scale commercial contracts for HA and other high-value specialty biochemicals like Human Milk Oligosaccharides (HMOs) or sustainable aviation fuels. A major pharmaceutical or chemical incumbent acquires Enzymit for its validated platform technology and expanding product pipeline at a significant premium, valuing the company at $337.5M (4.5x current valuation) or more, driven by its strong competitive moat and market leadership in cell-free bioproduction.

Base (50%)+150%

Enzymit continues to grow its hyaluronic acid business, achieving moderate market penetration and successfully expanding into one or two additional specialty biochemicals. The company secures a Series B round at a higher valuation, demonstrating solid execution, but faces ongoing intense competition in the broader synthetic biology space, limiting explosive growth. The company reaches a valuation of $187.5M (2.5x current valuation) within the 2-year horizon, reflecting steady progress and market traction.

Bear (25%)-80%

Enzymit faces significant challenges in scaling its cell-free production cost-effectively, or regulatory hurdles for its pharmaceutical and food-grade products prove more difficult and time-consuming than anticipated. Well-funded competitors with similar technologies or faster market entry capture significant market share. The company struggles to raise its next funding round, leading to a down round or a low-value acquisition at $15M (0.2x current valuation) or less, severely impacting common shareholder value due to liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $15M in liquidation preferences. In an exit at the current estimated $75M valuation, common shareholders would see value after the $15M preference is paid, effectively valuing common stock on $60M of the company's value.

Dilution Risk

high

As a Series A company, Enzymit will likely require multiple additional funding rounds (Series B, C, etc.) to scale, which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Enzymit's shares at this early stage.

Questions to Ask at the Interview

Strategic questions based on Enzymit's data — designed to show you've done your homework.

  • 1

    “Given the successful pilot-scale production of hyaluronic acid, what are the immediate next steps and key challenges in scaling this to full commercial production, and how is Enzymit addressing potential bottlenecks in supply chain or manufacturing infrastructure?”

  • 2

    “Enzymit's platform targets both hyaluronic acid and specialty biochemicals like sustainable aviation fuels and food-grade products. How does the company prioritize its product pipeline, and what is the strategy for balancing focus between established markets and emerging, high-growth opportunities?”

  • 3

    “With a Series A funding round completed in late 2024, what is the anticipated timeline for the next funding round (Series B), and how does the company envision achieving a liquidity event for employees, considering the current preference stack?”

Community

Valuation Sentiment

Our model estimates +143% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.